Page 108 - 2019_05-HaematologicaMondo-web

A.M. Vannucchi et al. References
1. Campbell PJ, Green AR. The myeloprolifer- ative disorders. N Engl J Med. 2006;355(23): 2452-2466.
2. Le Bousse-Kerdiles MC. Primary myelofi- brosis and the "bad seeds in bad soil" con- cept. Fibrogenesis Tissue Repair. 2012; 5(Suppl 1):S20.
3. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, patho- genesis, and treatment. Annu Rev Med. 2009;60:233-245.
4. Barosi G. Myelofibrosis with myeloid meta- plasia: diagnostic definition and prognostic classification for clinical studies and treat- ment guidelines. J Clin Oncol. 1999; 17(9):2954-2970.
5. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199-1203.
6. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reli- ability trial in 402 patients. Blood. 2011;118(2):401-408.
7. Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev. 2007;17(1):8-14.
8. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a vari- ety of cytokine receptors. Cell. 1998;93(3):385-395.
9. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best avail- able therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
10. Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-1707.
11. Verstovsek S, Mesa RA, Gotlib J, et al. Long- term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-con- trolled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55.
12. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of rux- olitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
13. Balduini A, Badalucco S, Pugliano MT, et al. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classi- cal myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes. PLoS One. 2011;6(6):e21015.
14. Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013;6(1):81.
15. Al-Ali HK, Vannucchi AM. Managing patients with myelofibrosis and low platelet counts. Ann Hematol. 2017; 96(4):537-548.
16. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symp- tom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring sys- tem among patients with MPNs. J Clin Oncol. 2012;30(33):4098-4103.
17. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
18. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76.
19. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibro- sis: the Mayo Clinic experience. Mayo Clin Proc. 2012;87(1):25-33.
20. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865-1871.
21. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
22. Harrison CN, Gisslinger H, Miller CB, et al. EXPAND: A phase 1b, open-label, dose- finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50×109/L and 99×109/L. Blood. 2012;120(21):177.
23. Griesshammer M, Vannucchi AM, le Coutre P, et al. Safety and efficacy of ruxolitinib in patients with low platelets enrolled in a phase 3b expanded-access study in myelofi- brosis (MF). Blood 2014; 124(21):1859.
24. Tavares R, Palumbo GA, Le Coutre P, et al. Safety and efficacy of ruxolitinib in an 1869- patient cohort of JUMP: an open-label, mul- ticenter, single-arm, expanded-access study in patients with myelofibrosis. Blood. 2015;126(23):2799.
25. Al-Ali HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in
the JUMP trial. Haematologica. 2016;
101(9):1065-1073.
26. JAKAFI® (ruxolitinib) prescribing informa-
tion USFDA. https:// www. accessdata.fda.gov/drugsatfda_docs/label/2 017/202192s015lbl.pdf. Accessed March 21, 2018.
27. JAKAVI® (ruxolitinib) Summary of product characteristics. http://www.ema. europa.eu/ docs/ en_GB/ document_library/EPAR_- _Product_Information/human/002464/WC5 00133223.pdf. Accessed March 21, 2018.
28. Verstovsek S, Gotlib J, Gupta V, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy out- comes. Onco Targets Ther. 2013;7:13-21.
29. Vannucchi AM, Gisslinger H, Harrison CN, et al. EXPAND: A phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis (MF) and low platelet counts (50×109/L to 99×109/L) at baseline. Blood. 2015;126(23):2817.
30. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
31. Mukuria C, Rowen D, Brazier JE, et al. Deriving a preference-based measure for myelofibrosis from the EORTC QLQ-C30 and the MF-SAF. Value Health. 2015;18(6):846-855.
32. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Res. 2009;33(9):1199-1203.
33. Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011; 117(21):4869- 4877.
34. Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis pre- viously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73-e81.
35. Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643-651.
36. Verstovsek S, Komrokji RS. A comprehen- sive review of pacritinib in myelofibrosis. Future Oncol. 2015;11(20):2819-2830.
954
haematologica | 2019; 104(5)